NLK blocking peptide product blog
Tags: Blocking Peptide; Nlk; Nlk blocking peptide; NLK-T286;
The NLK nlk (Catalog #MBS9230926) is a Blocking Peptide and is intended for research purposes only. The product is available for immediate purchase.The NLK nlk product has the following accession number(s) (GI #353678043) (NCBI Accession #NP_057315.3) (Uniprot Accession #Q9UBE8). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Serine/threonine-protein kinase that regulates a number of transcription factors with key roles in cell fate determination. Positive effector of the non-canonical Wnt signaling pathway, acting downstream of WNT5A, MAP3K7/TAK1 and HIPK2. Activation of this pathway causes binding to and phosphorylation of the histone methyltransferase SETDB1. The NLK- SETDB1 complex subsequently interacts with PPARG, leading to methylation of PPARG target promoters at histone H3K9 and transcriptional silencing. The resulting loss of PPARG target gene transcription inhibits adipogenesis and promotes osteoblastogenesis in mesenchymal stem cells (MSCs). Negative regulator of the canonical Wnt/beta-catenin signaling pathway. Binds to and phosphorylates TCF7L2/TCF4 and LEF1, promoting the dissociation of the TCF7L2/LEF1/beta-catenin complex from DNA, as well as the ubiquitination and subsequent proteolysis of LEF1. Together these effects inhibit the transcriptional activation of canonical Wnt/beta-catenin target genes. Negative regulator of the Notch signaling pathway. Binds to and phosphorylates NOTCH1, thereby preventing the formation of a transcriptionally active ternary complex of NOTCH1, RBPJ/RBPSUH and MAML1. Negative regulator of the MYB family of transcription factors. Phosphorylation of MYB leads to its subsequent proteolysis while phosphorylation of MYBL1 and MYBL2 inhibits their interaction with the coactivator CREBBP. Other transcription factors may also be inhibited by direct phosphorylation of CREBBP itself. Acts downstream of IL6 and MAP3K7/TAK1 to phosphorylate STAT3, which is in turn required for activation of NLK by MAP3K7/TAK1.
Cellular Location: Nucleus. Cytoplasm. Note: Predominantly nuclear. A smaller fraction is cytoplasmic (By similarity). The following patways have been known to be associated with this gene. Breast Neoplasms, Carcinoma, Hepatocellular, Cardiovascular Diseases, Cell Transformation, Neoplastic, Immune System Diseases, Liver Diseases, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Experimental are some of the diseases may be linked to NLK-T286 Blocking Peptide (Center). Blood, Bone, Bone Marrow, Brain, Embryonic Tissue, Eye, Liver, Lung, Lymph Node, Muscle tissues are correlated with this protein.